Abstract
Background
The introduction of novel systemic therapies for metastatic renal cell carcinoma (mRCC)
over the last decade has significantly improved patient outcomes. Little information
is available on treatment modalities and outcomes in everyday practice. The objective
of this study was to describe patient characteristics, treatment patterns, and healthcare
resource use in mRCC patients receiving systemic therapy in France (2014-2017), using
the nationwide claims database.
Patients and Methods
Patients with a diagnosis of RCC (ICD-10: C64) between 2009 and 2017 and receiving
a first systemic treatment for mRCC between 2014 and 2017 were eligible. Patients
were divided into two groups at diagnosis, Group A: metastatic RCC and Group B: localized
RCC.
Results
4,929 eligible patients were identified (Group A: 2638 patients, 53.5%; Group B: 2,291
patients,46.5%). Median age was 66 years and 73% were men. In patients with incident
RCC (N = 3,425), 62.3% underwent nephrectomy (94.4% in Group B). Within the year following
mRCC diagnosis, 86.5% were hospitalized at least once; among them 58.1% for RCC. Nearly
31% of patients underwent radiotherapy. First line treatment was sunitinib for 65%
of patients and pazopanib for 24%. Twenty five percent and 10% of patients received
2 and 3 lines of systemic treatment, respectively. The 2-year survival rate after
mRCC diagnosis was 44%, with median overall survival of 20 [95%CI: 19-21] months (14
and 28 in Group A and B).
Conclusion
This study documented patient characteristics, treatment patterns and survival outcomes
in mRCC patients receiving systemic therapy in France (2014-2017). Estimated survival
rates were consistent with real-world studies from other countries.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer. 2018; 103: 356-387
- Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. . Vol Volume 1 - Tumeurs solides.Étude à partir des registres des cancers du réseau Francim. Sante publique France, Saint‑Maurice2019
- The epidemiology of renal cell carcinoma.Eur Urol. 2011; 60: 615-621
- Renal cell carcinoma.Nat Rev Dis Primers. 2017; 3: 17009
- Renal cell carcinoma: diagnosis and management.Am Fam Physician. 2019; 99: 179-184
- Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v58-v68
- Race and renal cell carcinoma stage at diagnosis: an analysis of the surveillance, epidemiology, and end results data.Eur J Cancer Prev. 2019; 28: 350-354
- Cancer statistics, 2018.CA Cancer J Clin. 2018; 68: 7-30
- Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger.Ann Oncol. 2019; 30: 706-720
- Systemic treatment of renal cell cancer: a comprehensive review.Cancer Treat Rev. 2017; 60: 77-89
- Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.Curr Med Res Opin. 2017; 33: 1755-1762
- Patient characteristics and treatments one year after diagnosis of renal cancer in 2015 according to the presence or absence of metastasis and a history of another tumour: a national observational study.Bull Cancer. 2019; 106: 538-549
- French administrative health care database (SNDS): the value of its enrichment.Therapie. 2019; 74: 215-223
- Etude des algorithmes de définition de pathologies dans le système national d'information inter-régimes de l'assurance maladie (SNIIRAM).Caisse nationale d'Assurance maladie des travailleurs salariés, Paris2015
- European association of urology guidelines on renal cell carcinoma: the 2019 update.Eur Urol. 2019; 75: 799-810
- Kidney Cancer, version 2.2017, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2017; 15: 804-834
- [French ccAFU guidelines - update 2018-2020: management of kidney cancer].Prog Urol. 2018; 28: R5-R33
- Is the type 2 diabetes epidemic plateauing in France? a nationwide population-based study.Diabetes Metab. 2020; 46: 472-479
- Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en 2012.Bull Epidémiol Hebd. 2014; 30-31: 493-499
- L'hypertension artérielle en France: prévalence, traitement et contrôle en 2015 et évolutions depuis 2006.Bull Epiemiol Hebd. 2018; 10: 170-179
- 2017 Annual report digest of the renal epidemiology information network (REIN) registry.Transpl Int. 2019; 32: 892-902
- Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2014; 25: iii49-iii56
- In-hospital economic burden of metastatic renal cell carcinoma in france in the era of targeted therapies: analysis of the french national hospital database from 2008 to 2013.PLoS One. 2016; 11e0162864
- Immune checkpoint blockade in renal cell carcinoma.J Surg Oncol. 2021; 123: 739-750
- Factors influencing overall survival for patients with metastatic clear-cell renal-cell carcinoma in daily practice.Clinical genitourinary cancer. 2018; 16: e297-e305
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.Eur J Cancer. 2013; 49: 1287-1296
- Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol. 2009; 27: 3584-3590
- Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.BMC Cancer. 2020; 20: 670
Article info
Publication history
Published online: July 23, 2022
Accepted:
July 21,
2022
Received:
March 11,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
